The Non-Malignant Channel is supported with funding from Agios (Gold).
The Sickle Cell Disease Channel is supported with funding from Agios (Gold).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2024 | An update on the Phase I/II RUBY trial of reni-cel gene therapy in patients with severe SCD
Rabi Hanna, MD, The Cleveland Clinic Taussig Cancer Institute, Cleveland, OH, presents the interim analysis of the RUBY Phase I/II trial (NCT04853576) evaluating renizgamglogene autogedtemcel (reni-cel) for patients with severe sickle cell disease (SCD). The results were promising, with patients exhibiting rapid platelet and neutrophil engraftment post-infusion. Additionally, all patients experienced no pain crises during the median follow-up of 7 months post-infusion (range: 2.8 months to 2 years), a significant decrease from a median of 5.2 pain crises per year prior to treatment. This interview took place at the 29th Congress of the European Hematology Association (EHA) in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Speakers Bureau: SOBI, Sanofi
Honoraria: Vertex
Research Funding: EDITAS
